Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity
Authors:
- Chih-Ping MaoCMChih-Ping Mao
- Sung Yong LeeSLSung Yong Lee
- Alexander ChenACAlexander Chen
- Ji-Hyun LeeJLJi-Hyun Lee
- Tae Woo KimTKTae Woo Kim
- Ronald D. AlvarezRARonald D. Alvarez
- Richard B.S. RodenRRRichard B.S. Roden
- Drew PardollDPDrew Pardoll
- Chien-Fu HungCHChien-Fu Hung
- T.-C. WuTWT.-C. Wu
- 15 April 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (8) , 2493-2504
Abstract
Multiple classes of pharmacologic agents have the potential to induce the expression and release of proinflammatory factors from dying tumor cells. As a result, these cells can in theory elicit an immune response through various defined mechanisms to permanently eradicate disseminated cancer. However, the impact of chemotherapy on the tumor-specific immune response in the context of the tumor microenvironment is largely unknown. Within the tumor microenvironment, the immune response promoted by chemotherapy is antagonized by an immune-suppressive milieu, and the balance of these opposing forces dictates the clinical course of disease. Here, we report that high antigen exposure within the tumor microenvironment following chemotherapy is sufficient to skew this balance in favor of a productive immune response. In elevating antigen exposure, chemotherapy can achieve long-term control of tumor progression without the need of an additional adjuvant. We found that chemotherapy initiated this phenomenon in the tumor microenvironment through an accumulation of dendritic cells, which stimulated CD8+ T cells and the type I IFN pathway. From this conceptual base, we developed a simple approach to cancer therapy combining chemotherapy and vaccination that may be widely applicable. Cancer Res; 73(8); 2493–504. ©2013 AACR.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to ResistanceCancer Cell, 2012
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasiaBritish Journal of Cancer, 2010
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma PatientsClinical Cancer Research, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cellsJournal of Experimental Medicine, 2007
- Keratinocyte-Derived Monocyte Chemoattractant Protein 1 (MCP-1): Analysis in a Transgenic Model Demonstrates MCP-1 Can Recruit Dendritic and Langerhans Cells to SkinJournal of Investigative Dermatology, 1995